معرفی
Cynthia Miranti is a Professor in the Department of Cellular and Molecular Medicine at the University of Arizona. She serves as Chair of the Cancer Biology Graduate Interdisciplinary Program (GIDP), Co-Program Leader for the Cancer Biology Research Program, and holds an appointment at the BIO5 Institute. Her research focuses on prostate cancer, particularly the role of the tumor microenvironment in disease progression, metastasis, and hormonal drug resistance.
- B.A. in Microbiology - Southern Illinois University
- M.S. in Microbiology - Colorado State University
- Ph.D. in Biochemistry - Harvard Medical School
- Postdoctoral Fellow - ARIAD Pharmaceuticals and Harvard Medical School
Miranti's research program centers on three areas: Prostate-on-a-Chip models, bone metastasis signaling pathways, and castration-resistant prostate cancer mechanisms. She investigates how hypoxia and bone microenvironmental signals contribute to drug resistance via Bnip3, PIM kinase, and androgen receptor (AR) activation. Her work combines genetics, cell biology, and molecular biology in in vitro and in vivo models to address clinically relevant challenges in prostate cancer.
Her recent publications highlight trends in integrin α6β1 signaling, AR regulation, PIM kinase roles in angiogenesis and drug resistance, and CD82's dual functions in prostate cancer metastasis suppression and immune signaling. Key subfields include mitophagy, anti-ROS signaling, NOTCH3-MMP-3 interactions, and microfluidic cancer modeling.
Miranti's lab operates within the University of Arizona Cancer Center. She has mentored numerous researchers and collaborates extensively on studies involving tumor-stroma interactions, cytoskeletal dynamics, and precision therapy development.
